Eileen P. Connolly, MD, PhD

Radiation Oncology (Board Certified, Primary Specialty)
Cancer Care

Biography

Eileen Connolly, M.D., Ph.D. is Assistant Professor of Radiation Oncology at New York Presbyterian/Columbia University Medical Center. She is a board-certified radiation oncologist who cares for patients with all types of cancer but specializes in the treatment of breast and pediatric malignancies with radiation therapy. Dr. Connolly has published various articles in her field, including several related to breast cancer. In addition to her breast research she participates in a number of Children’s Oncology Group (COG) protocols for the treatment of pediatric malignancies and works closely with the Pediatric Oncology group at Morgan Stanley Children's Hospital of New York-Presbyterian/Columbia University Medical Center.

Dr. Connolly received her M.D./Ph.D. degree, internal medicine and radiation oncology training at New York University School of Medicine, where she was Chief Resident of Radiation Oncology. During her residency training she received both the 2010 Varian Medical Systems/RSNA Research Resident Grant and the 2010 ASTRO Residents/Fellows in Radiation Oncology Award. In addition, Dr. Connolly was trained in Gamma Knife Radiosurgery at the University of Pittsburgh Medical Center - Center for Image-Guided Neurosurgery, pioneers in the field of stereotactic radiosurgery for brain cancers and malformations.

Besides her clinical duties Dr. Connolly is the director of a translational research laboratory in the Center for Radiological Research (CRR) in which she pursues her research interests in understanding the mechanisms of radiation resistance of cancer. Specifically her work focuses on the PI3K/Akt pathway with a goal of developing targeted agents that may be used as radiation sensitizers to reduce the risk of local recurrence. For her research she has received the 2012 Radiological Society of North America (RSNA) Research Seed grant, and a 2012 Irving Institute/Clinical Trials Office Pilot Award.

Area of Expertise

Please contact the doctor's office to verify that your insurance is accepted.

Aetna [EPO, HMO, Medicare, NY Signature, POS, PPO, Signature Administrators, Student Health]

Affinity [Access (Exchange), Essential Plan, Medicaid Managed Care, Medicare Managed Care]

Amida Care

Cigna [EPO, Great West, HMO, POS, PPO]

Emblem/HIP [ConnectiCare, EPO, Essential Plan, HMO, Medicaid Managed Care, Medicare Managed Care, POS, PPO, Select Care (Exchange), Vytra]

Empire Blue Cross Blue Shield [Blue Priority, EPO, HMO, Medicare (Mediblue), NYP Employee Plan, Pathway (Exchange), POS, PPO]

Empire Blue Cross Blue Shield HealthPlus [Child/Family Health Plus, Essential Plan, Medicaid Managed Care]

Fidelis Care [Child/Family Health Plus, Medicaid Managed Care, Medicare Managed Care]

Healthfirst [Child/Family Health Plus, Medicaid Managed Care, Medicare Managed Care]

Local 1199

MagnaCare

Medicare [Medicare]

Multiplan

Oxford Health Plans [Freedom, Liberty, Medicare Managed Care]

POMCO

UnitedHealthcare [Columbia University Employee Plan, Compass (Exchange), EPO, HMO, Medicaid (Community Plan), Medicare Managed Care, POS, PPO, The Empire Plan (NYSHIP)]

VNSNY CHOICE [SelectHealth]

Education

New York University School of Medicine

New York University

Internship: New York University Langone Medical Center

Residency: New York University Langone Medical Center

Publications

  • Connolly, E., Braunstein, S., Formenti, S., and Schneider, R.J. Hypoxia inhibits protein synthesis through a 4E-BP1 & elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells. Mol Cell. Biol. 2006 May; 26(10):3955-65.
  • Connolly, E, Thuiller, V., Rouy, D., Bouetard, G., and Schneider, R.J. Inhibition of Cap-Initiation complexes linked to a novel mechanism of eIF4G depletion in acute myocardial ischemia. Cell Death and Diff. 2006 Sept;13(9):1586-94.
  • Ioffe E, Moon B, Connolly E, Friedman JM. Abnormal regulation of the leptin gene in the pathogenesis of obesity. Proc. Natl. Acad. Sci. USA 1998; 95:11852-7.
  • Li C, Ioffe E, Fidahusein N, Connolly E., Friedman J.M. Absence of soluble leptin receptor in plasma from dbPas/dbPas and other db/db mice.J Biol Chem. 1998. 273:10078-82.
  • Hung CF, Holzmacher R, Connolly E, Berenbaum MR, Schuler MA. Conserved promoter elements in the CYP6B gene family suggest common ancestry for cytochrome P450 monooxygenases mediating furanocoumarin detoxification. Proc. Natl. Acad. Sci. USA 1996.93:12200-5.

Abstracts & Presentations

  • Connolly E.P., Silvera D., Badura, M.L., Venuto T.A., Schneider R.J. (2011). Over-expression of translation initiation factor eIF4G confers robust radioresistance to the cancer stem cell population in inflammatory breast cancer. American Society for Therapeutic Radiology and Oncology (ASTRO) 53nd Annual Meeting, Miami, FL – Oral presentation
  • Connolly E.P., Silvera D., Venuto T.A., Sawai R., Schneider R.J. (2011). TORC1/2 inhibition with concurrent radiation controls inflammatory breast cancer in a preclinical animal model through selective blockade of translation. American Society for Therapeutic Radiology and Oncology (ASTRO) 53nd Annual Meeting, Miami, FL – Poster
  • Connolly E.P., Silvera D., Venuto T.A., Formenti S.C., Schneider R.J. (2011). Catalytic but not allosteric inhibition of mTOR radiosensitizes inflammatory breast cancer tumors in an animal model. AACR special conference – Targeting PI3K/mTOR signaling in Cancer, San Francisco, CA – Poster
  • Silvera D., Connolly E.P., Badura, M.L., Venuto T.A., Schneider R.J. (2011). Translation initiation factor eIF4G confers radio-resistance to the cancer stem cell population in advanced breast cancers. AACR special conference – Targeting PI3K/mTOR signaling in Cancer, San Francisco, CA – Poster

Assistant Professor of Radiation Oncology at CUMC